Advertisement
Advertisement
U.S. markets close in 4 hours 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ZLAB Dec 2022 80.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.51000.0000 (0.00%)
As of 12:31PM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • Bloomberg

    Latest Push by Chinese Firms to Avoid Delistings Falls Short

    (Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark

  • Benzinga

    Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

    Seagen Inc (NASDAQ: SGEN) and Zai Lab Limited (NASDAQ: ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for treating adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The collaboration supports regional patient enrollment for InnovaTV 301

  • Business Wire

    Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

    BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass., September 27, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the

Advertisement
Advertisement